Harry J. Leonhardt

2018 - Halozyme Therapeutics

In 2018, Harry J. Leonhardt earned a total compensation of $1.9M as Senior Vice President, General Counsel at Halozyme Therapeutics, a 7% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$304,218
Option Awards$575,009
Salary$442,000
Stock Awards$575,018
Other$11,355
Total$1,907,600

Leonhardt received $575K in stock awards, accounting for 30% of the total pay in 2018.

Leonhardt also received $304.2K in non-equity incentive plan, $575K in option awards, $442K in salary and $11.4K in other compensation.

Rankings

In 2018, Harry J. Leonhardt's compensation ranked 5,985th out of 14,244 executives tracked by ExecPay. In other words, Leonhardt earned more than 58.0% of executives.

ClassificationRankingPercentile
All
5,985
out of 14,244
58th
Division
Manufacturing
2,278
out of 5,759
60th
Major group
Chemicals And Allied Products
853
out of 2,122
60th
Industry group
Drugs
713
out of 1,811
61st
Industry
Biological Products, Except Diagnostic Substances
138
out of 339
59th

Pay ratio

Harry J. Leonhardt's Pay$1,907,600
Median Employee's Pay$199,899
Pay Ratio

10

to 1

In 2018, the annual total compensation of Harry J. Leonhardt was $1,907,600.

The annual total compensation of the median employee at Halozyme Therapeutics was $199,899.

The ratio of Harry J. Leonhardt's pay to the pay of median employee was therefore 10 to one.

Source: SEC filing on March 22, 2019.

Leonhardt's colleagues

We found four more compensation records of executives who worked with Harry J. Leonhardt at Halozyme Therapeutics in 2018.

2018

Helen Torley

Halozyme Therapeutics

Chief Executive Officer

2018

Benjamin Hickey

Halozyme Therapeutics

Senior Vice President and Chief Commercial Officer

2018

Laurie Stelzer

Halozyme Therapeutics

Chief Financial Officer

2018

Dimitrios Chondros

Halozyme Therapeutics

Chief Medical Officer

News

You may also like